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Summary 
The mechanisms  of sustained  overproduction of eosinophils in  the  idiopathic hypereosino- 
philic syndrome and in some human immunodeficiency virus (HIV)-l-infected individuals are 
largely unknown. We hypothesized that T cells may release soluble products that regulate eosi- 
nophi]ia in these patients, as has been previously shown in bronchial asthma. We identified one 
patient with idiopathic hypereosinophilic syndrome and one HIV-l-infected individual with 
associated hypereosinophilia who demonstrated high numbers of CD4-CD8-  T  cells in pe- 
ripheral blood. CD4-CD8-  T  cells from both patients, although highly activated, did not ex- 
press  functional Fas receptors. In one case,  the lack of functional Fas receptors was associated 
with failure ofFas mR.NA and protein expression, and in another, expression of a soluble form 
of  the Fas molecule that may have antagonized normal signaling ofFas ligand. In contrast to the 
recently described lymphoproliferative/autoimmune syndrome, which is characterized by ac- 
cumulation of CD4-CD8-  T  cells and mutations within the Fas gene, this study suggests  so- 
matic variations in Fas expression and function quite late in life. Both genetic and somatic ab- 
normalities in regulation of the Fas gene are therefore associated with failures to undergo T cell 
apoptosis.  Furthermore, the expanded population of CD4-CD8-  T  cells from both patients 
elaborated cytokines with antiapoptotic properties for eosinophils, indicating a major role of 
these T  ceils  in the development of eosinophilia. Thus, this study demonstrates a sequential 
dysregulation ofapoptosis in different cell types. 
E 
xpansion of CD4-CD8-  T  cells has been observed in 
patients with a syndrome characterized by hypergam- 
maglobtrlinemia,  lymphocytosis, hepatosplenomegaly, lymph- 
adenopathy, and autoimmunity (1).  In two recent reports, 
mutations  within  the  Fas  gene  were  associated with  this 
disorder (2, 3). Fas is a ceil-surface protein that plays a major 
role in induction ofapoptosis in lymphoid cells. Therefore, 
mutations  within  the  Fas  gene  result  in  defects  of Fas- 
induced apoptosis (2, 3). Moreover, the clinical, immuno- 
logical, and molecular features of this human lymphoprolif- 
erative syndrome are reminiscent of those observed in lpr/ 
lpr mice (1-3). 
Eosinophilic granulocytes are proinflammatory cells that 
are primarily involved in immune defense against  parasites. 
Furthermore, they play a major role in late-type inflamma- 
tory reactions, and are prominent in many chronic inflam- 
matory diseases,  particularly in allergic manifestations such 
as bronchial asthma and atopic dermatitis (4, 5). It has been 
shown that these diseases can be associated with an increase 
of activated T  cells that regulate eosinophilia by the release 
of cytokines  such  as  IL-3,  IL-5,  and  GM-CSF  (6-8). 
Among T  cells,  the  CD4 +  cells  have been considered as 
major producers  of eosinophil  survival  factors in  human 
bronchialasthma (9) and in animal models (10). In contrast, 
the  pathogenesis  of eosinophilia in  the  idiopathic  hyper- 
eosinophilic syndrome (11) and in HIV-infected individu- 
als (12) is largely unknown. 
In  this  article, we  describe the  accumulation  of CD4- 
CD8-  T  cells due to abnormal Fas expression in two pa- 
tients  with  hypereosinophilia,  suggesting  that  these  cells 
can not undergo apoptosis via the Fas pathway. In contrast 
to the recently published work where expansion of CD4- 
CD8-  T  cells  was  associated  with  mutations  of the  Fas 
gene  (2,  3),  the  results  of our study suggest  that somatic 
variations in Fas expression and function may also lead to 
defects in Fas-induced apoptosis. The consequences of such 
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of regulatory cytokines for eosinophil growth and survival 
resulting in chronic inflammation. 
Materials and Methods 
Patients.  Patient 1 was a 64-yr-old man with a 20-yr history 
of idiopathic hypereosinophilic syndrome. The laboratory find- 
ings  included  marked  eosinophilia (4,420/n~m  3)  in  the  blood, 
liver, and bone  marrow.  Because  of fluctuating symptoms and 
eosinophiha, ongoing treatment with steroids was required. After 
a 10-yr course of the disease, diarrhea became increasingly prom- 
inent. Gastrointestinal biopsies revealed a severe eosinophilic gas- 
troenteritis. As a result of chronic gastroenteritis, the patient de- 
veloped hypogammaglobuhnemia. Absolute and relative B  cell 
numbers were normal and autoantibody production was not ob- 
served. 20 yr after onset of initial symptoms, the patient died of a 
nonocclusive  small  bowel  infarction  with  peritonitis.  Studies 
were done using peripheral blood taken 2-4 mo before the pa- 
tient's death. At this time, the patient had a peripheral blood eosi- 
nophiha of 11-14%, despite treatment with 50 mg ofprednisone. 
Immunohistochemistry and genotypic studies were performed on 
both small intestine and colon specimens that were obtained after 
the patient's death. 
Patient 2 was an HIV-l-infected, 37-yr-old man with recur- 
rent skin lesions, oral candidiasis, and hypereosinophilia (3,690/ 
mm3).  The patient had a high serum IgE level (4.00  kU/hter), 
but normal levels for IgG, IgM, and IgA. Absolute and relative B 
cell numbers were normal, and autoantibodies were not detected. 
The patient did not suffer from allergic diseases or atopic dermati- 
tis, nor did he show any documented inflammatory skin lesions 
before his seroconversion to HIV-1. He also  had no  detectable 
parasitic infection. Studies were  done using blood taken before 
and after a 100-mg prednisone treatment that lasted 2 d. Despite 
this treatment, the patient maintained a peripheral blood eosino- 
philia of 41%. 
Collection of Blood and Bronchoalveolar Lavage.  Heparin  antico- 
agnlated blood (I00 rnl) was collected between 7:30 and 8:00 a.m. 
Bronchoalveolar lavage (BAL) 1 was performed according to the 
technical recommendation and guidelines of the Task Group on 
BAL of the European Society of Pneumology. Briefly, 3 ￿  50 ml 
of 0.9% NaC1 was instilled in the middle lobe, immediately aspi- 
rated into plastic tubes using a vacuum suction system, and kept 
at 4~ 
Immunofluorescence Analysis,  To determine T lymphocyte sub- 
sets, cells were incubated in different combinations with FITC- 
or PE-conjugated mAbs against CD3  (clone UCHT1,  this anti- 
body reacts with human CD3e; Dako, Zurich, Switzerland), CD4, 
CD8, CD16, and CDI9. Purified CD4-CD8- T cells were ana- 
lyzed with mAbs against TCR.-et/I3 (Pan-TCR.-~x/I3)  and TCR.- 
~/8 (TCR-M) (both from T Cell Diagnostics, Cambridge, MA). 
To analyze T  cell activation, cells were incubated with FITC- 
or PE-conjugated mAbs  against CD4,  CD8,  CD25  (IL-2R c~ 
chain), and HLA-DR. The distribution ofCD45 isoforms was as- 
sessed on T ceils by incubation with PE-conjugated anti-CD45RA 
(naive T cells) and CD45R.O (memory T cells, both from Dako). 
The  usage of different VI3  elements of TCR.  was  measured 
with the following FITC-conjugated mAbs: anti-VI32 (lmmuno- 
tech,  Marseille, France), anti-VI35(a),  anti-V135(b),  anti-V~5(c), 
1Abbreviations used in this"  paper: BAL, bronchoalveolar lavage; nt, nude- 
otide, 
anti-VI36, anti-VI38, anti-VI312 (all from T Cell Diagnostics), and 
anti-VI319 (Immunotech). 
To  determine  protein  expression of the  Fas molecule,  two 
anti-Fas  mAbs  (IgM  from  Biomol,  Hamburg,  Germany)  and 
IgG3 (a kind gift from Dr. P.H. Krammer, German Cancer P,.e- 
search Center, Heidelberg, Germany) were used. For both mAbs, 
cells were incubated at 4~  for 1 h.  Since these mAb were not 
conjugated, cells were additionally incubated with PE-conjugated 
goat  anti-mouse  Ab  (Tago-Inotech,  Dottikon,  Switzerland)  at 
4~  for 30 rain. 
Unless  stated otherwise,  all other  mAbs were  from  Coulter 
(Instrumentation Laboratory, Schlieren, Switzerland). All incuba- 
tions were performed with saturating concentrations of mAb ac- 
cording to the manufacturer's instructions. Cells were analyzed 
using a cytofluorograph (Epics Profile or Epics XL; Coulter, Hi- 
aleah,  FL).  The  number  of immunofluorescence-positive cells 
was determined in 5,000 analyzed cells. Specific binding of mAb 
was controlled by subtraction ofisotype-matched control mAbs. 
Immunocytochemistry.  Cryopreserved postmortem  colon  sec- 
tions from patient 1 were fixed in acetone for 5 rain at -20~ 
air-dried, and blocked for 20 min with PBS containing 10% goat 
serum. Adjacent sections were exposed with mAbs to anti-CD2, 
anti-CD3, anti-CD4, anti-CD5, anti-CD8 (all from Dako), anti- 
TCK-a/13 (13F1), and anti-TCR-',//~ (TCR~I; both from T Cell 
Diagnostics), for 30 min, washed extensively in PBS, and subse- 
quendy  incubated with  peroxidase-conjugated anti-mouse  IgG 
diluted 1:80  in PBS containing 2% goat serum and 10% human 
serum. Diaminobenzidine was used as a substrate,  and Mayer's he- 
matoxyhn was used as counterstain. Frozen tonsil sections served as 
positive controls. 
Cell Purifications.  T  cells were isolated from blood as previ- 
ously described (13).  Briefly, PBMC  were  obtained by  Ficoll- 
Hypaque (Seromed-Fakola AG, Basel, Switzerland) density gradi- 
ent centrifugation. To purify the CD4-CD8-  T  subpopulation, 
cells were  incubated with  anti-CD14,  anti-CD16,  anti-CD19, 
anti-CD4, and anti-CD8 mAbs (Imanunotech). Cells were washed 
twice with PBS/0.5% BSA, and were incubated with goat anti- 
mouse  IgG  magnetic  microbeads  (Miltenyi Biotec,  Bergisch- 
Gladbach, Germany) for 15 roan at 10~  T cells were then nega- 
tively selected by an immunomagnetic procedure incorporating 
the MACS system (Miltenyi Biotec). 
To obtain in vivo-activated T cells for functional Fas-mediated 
apoptosis assays, one  patient with  hypersensitivity pneumonitis 
was selected. A  sample of BAL fluid of this patient was faltered 
through a 70-1*m nylon mesh (Falcon, Basel, Switzerland). Cells 
were centrifuged at 500 g  for 10  min and resuspended in PBS. 
Cytologic examination of the BAL fluid was done after cytocen- 
trifugation and staining with May-Gruenwald-Giemsa. The BAL 
fluid of this patient contained 80% lymphocytes. To further en- 
rich the lymphocyte fraction, cells were centrifuged over a Per- 
coil density gradient (Pharmacia Biotech,  Diibendorf,  Switzer- 
land). The  resulting cell pellet consisted of 96%  pure  CD3 + T 
cells, as assessed by flow cytometry. 
Eosinophil purification was performed as previously described 
(13--15). 
Cell Cultures and Cell Lines.  To  prepare  cell  supernatants, 
PBMC, purified CD4 + T cells, and purified CD4-CD8- T  cells 
were cultured at 2 ￿  106 cells/200 Ixl in 96-well plates (Falcon). 
In some experiments, cells were stimulated with 10 Ixg/ml PHA 
(Boehringer Mannheim,  Rotkreuz,  Switzerland). After incuba- 
tion for 24 h  at 37~  in  5%  CO2  in a fully humidified atmo- 
sphere, the supernatants were harvested and frozen at -80~  un- 
til analysis. 
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viduals were incubated with anti-CD3 mAb (0.5  Ixg/rrd OKT 3; 
American Type Culture Collection, Kockville, MD) for 48 h and 
cultured as described above. 
For  comparisons with  in  vivo- and  in  vitro-activated non- 
transformed T cells, the human T cell hne Jurkat was used. Jurkat 
cells were maintained by serial passage in tLPMI 1640 containing 
10% FCS (complete medium), and were used in their logarithmic 
growth phase. 
RNA Isolation and cDNA Synthesis.  Using an RNA purifica- 
tion  kit  (Stratagene,  Heidelberg,  Germany), RNA  was isolated 
from 5  ￿  106 lymphocytes (PBMC or purified T  cell subsets)  or 
from 2  ￿  107 purified eosinophils derived from the patient with 
hypereosinophilic syndrome. First-strand cDNA synthesis was per- 
formed using total lymphocyte or eosinophil RNA, random hexa- 
deoxynucleotides at 0.2  ~g/~l as primers, and Moloney murine 
leukemia virus reverse transcriptase (Pharmacia) as previously de- 
scribed (15,  16). 
CD8a, CD8~, CD3T, and Fas mRNA Expression.  mRNA ex- 
pression was detected by a PCR technique. Primers for CD8cx am- 
phfication were obtained from Clontech (LucernaChem, Lucerne, 
Switzerland).  Primers for CD8~ (5'-CTCCATGGCAACTCAG- 
TCCTCC-3'  and  5'-CCTGAGGTAACCGGCACACTCT- 
CTTC-3'),  CD3~/  (5'-GGGGAAGGGCCTGGCTGTCC-3' 
and 5'-CCCAACAGCAAGGACGAAAATGC-3'), and for Fas 
(5'-GTGGGATCCCACTTCGGAGGATTGCTCAACAACC- 
3'  and  5'-GTGCTGCAGTATGTTGGCTCTTCAGCGCTA- 
ATA-3') amphfications were synthesized according to previously 
pubhshed  sequences  (17-19).  After amphfication,  8  ~1 of PCR 
product was mn on 1% agarose gel and stained by ethidium bromide. 
DNA Sequencing.  PCR products after Fas amphfication were 
subcloned into pCR  TM  II (Invitrogen, San Diego, CA). The plas- 
mid DNA was sequenced directly by dideoxy chain termination 
using the Sequenase  sequencing method (U.S. Biochemical Corp., 
Cleveland, OH). 
Analysis of Fas-mediated Cell Death.  To determine the cytolytic 
effect of anti-Fas mAb (Biomol), purified T  cell subsets from the 
two patients with eosinophilia, resting and in vitro-activated non- 
transformed T  cells  from normal individuals,  in  vivo-activated 
BAL T  cells  from a  patient  with  hypersensitivity pneumonitis, 
and Jurkat cells were cultured in the presence of 0.5 ~g/ml anti- 
Fas mAb for 18 h. Cell viability was assessed by flow cytometry (14). 
Bioassay to Determine Soluble Fas Activity.  106/ml  Jurkat  cells 
were cultured in complete cukure medium with 0.5 Ixg/ml anti- 
Fas mAb (Biomol) in the presence of supernatants (final dilution 
=  1:4)  derived from PBMC and purified T  cell subsets  of both 
patients for 18 h.  In addition,  supernatants from normal human 
resting  and  PHA-activated  PBMC  were  used  as  comparisons. 
Cell viability was assessed by flow cytometry (14). 
Analysis of TCR Gene Rearrangement Patterns.  Original proto- 
cols to analyze TCIL-J3 gene rearrangements by Southern blot- 
ring were used (20).  Nitrocellulose filters  (Schleicher & Schuell, 
Dassel,  Germany)  were  hybridized  with  a  digoxigenin-labeled 
TCK-c[31 cDNA probe (21). Color detection was done by using 
a digoxigenin nucleic acid detection kit (Boehringer Mannheim). 
Bioassay to Determine Eosinophil Survival Factors.  The determi- 
nation of eosinophil viability was performed by flow cytometry as 
previously described (14). 
Cytokine Protein Expression.  The expression of cytokines that 
prolong eosinophil viability in vitro,  IL-3, IL-5, GM-CSF,  and 
IFN-% was measured in culture  supernatants from PBMC  and 
purified T cells by ELISA (22). 
Cytokine mRNA Expression.  To determine cytokine gene ex- 
pression in PBMC, T  cell subsets,  and eosinophils, a PCtL tech- 
nique  using  oligonucleotides  that  recognize  specific  sequences 
within cytokine genes was used (15). In addition, J3-actin amplifi- 
cation was performed to control the quality of cDNA samples. 
Primers for the following cytokines were used:  IL-2, IL-3, IL-4, 
IL-5,  IL-6,  TNF-ot,  IFN-%  and  GM-CSF  (all from Clontech 
Laboratories, Palo Alto, CA). All primers have been designed to 
span an intron within the cytokine genes. Amphfication of any 
residual genomic DNA would therefore appear as an unexpected, 
larger PCIL product. After amphfication, 8 ~  of each PCtL prod- 
uct was run on 1% agarose gel and transferred to a nitrocellulose 
filter (Schleicher & Schuell).  Kadioactive probes were made using 
random priming (Ohgonucleotide Labehng Kit; Pharmacia) from 
the appropriate cytokine cDNA, and the filters were hybridized 
with 32p-labeled  cytokine probes. 
Results and Discussion 
Identification  of CD4-CD8-  T  Cells  in Blood and  Tissue. 
Most mature T  cells express either CD4 or CD8 molecules 
on their  surface.  In two patients  with high blood  eosino- 
philia, however, we observed high numbers of CD4-CD8- 
T  cells (15 and  18% within the lymphocyte population)  in 
blood (Fig.  1 A, b and c, and Bc). These T  cells were TCIk- 
ot/[3 + and TCtL-8/&d-  (Fig.  1 A, e and f, and B, e and f). 
In addition,  microscopic  evaluation  of purified  cells indi- 
cated a lymphocytic morphology (data not shown).  Studies 
on  normal  blood  cells  from  50  donors  revealed  that  the 
CD4-CD8-  T  subpopulation  usually does not exceed 3% 
within the lymphocyte population  (data not shown).  In ad- 
dition,  using  the  postmortem  tissue  of one  patient,  we 
showed the presence of these cells in colon tissue. The tissue 
CD4-CD8-  T  cells were  CD3 +  (Fig.  2  A)  and  TCIL{3 + 
(Fig. 2 E), but CD5-  (Fig. 2  C) and TCtLS-  (Fig. 2 F-). 
In  Vivo Clonality of CD4- CDS-  T  Cells.  We  have  at- 
tempted to identify the origin of the patient's CD4-CD8- 
T  cell populations.  Since purified CD4-CD8-  T  cells from 
both patients did not express CD16  (data not shown),  it is 
unlikely  that  they  represent  so-called  large  granular  lym- 
phocytes  (23,  24).  In  addition,  since  these  cells  were 
TCtL[3 + and TCtLg-  (Figs.  1 and 2), it was concluded that 
they did not belong to the ~//8+  CD4-CD8-  T  cell subset 
(25-27). 
It has been  recently  shown  in  mice  that  CD8 +  T  cells 
develop  into  CD4-CD8-  T  cells in the  presence  of IL-4 
(28).  In  this  in  vitro  system,  IL-4  downregulates  the  ex- 
pression oYCD8oL, but not of CD813 (28). We therefore in- 
vestigated the  expression of CD8oc and CD813  by purified 
CD4-CD8-  T  cells  using  PCR  and  specific  primers  for 
both  genes.  As shown  in  Fig.  3,  CD4-CD8-  T  cells de- 
rived  from  patients  1  and  2  did  not  express  CD8~  or 
CD813,  suggesting  that  they  are  distinct  from  those  oh- 
served  in  the  murine  in  vitro  model.  Furthermore, 
CD4-CD8-  cells from both patients expressed mRNA  for 
CD3~/  confirming  that  they  indeed  represented  T  cells 
(Fig. 3). 
To investigate whether the increased numbers of CD4- 
CD8-  T  cells may be the result of a monoclonal T  cell ex- 
pansion,  DNA  was extracted from the  highly T  ceU-infil- 
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Figure 1.  Identification  of  CD4-CD8  T cells in peripheral blood. (A) 
H1V-l-infected individual (patient 2).  (a) Dot plot of forward vs side 
light scatter of  peripheral blood cells by flow cytometry showing "gated" 
lynThocytes that were later analyzed by two-color immunofluorescence. 
(b and  c)  Two-color  immunofluorescence analysis of blood  cells. No 
CD3+CD4 + T cells were observed. 15% of the lymphocyte fraction con- 
tained CD3+CD4-CD8  - T cells. (d-h) Two-color immunofluorescence 
analysis of purified CD4  CD8- T cells. Cells were purified by negative 
selection. CD4-CD8  T cells were TCla,  c~/13  + and TCR-//g-. Further- 
more, they were highly activated as they expressed high levels of CD25 
and HLA-DR.. (B) Patient with idiopathic hypereosinophilic syndrome 
(patient 1). (a-c) Two-color immunofluorescence analysis of blood cells. 
18% of the lymphocyte fraction contained CD3+CD4-CD8  T  cells. 
(d-f) Two-color immunofluorescence  analysis of purified CD4  CD8  T 
cells. Cells were purified by negative selection. CD4-CD8- T cells were 
TCRc~/[3  + and TCRy/g-. Numbers at the upper right comer of each 
region indicate the percentage of  positively stained cells. 
trated  colon  of patient  1,  and  Southern  blot  analysis  was 
performed using a probe of a constant region of the [3 chain 
of the TCR  gene. Fig. 4 A  demonstrates a band(s) in addi- 
tion to the germ_line bands that indicates a pattern of clonal 
rearrangement.  Thus,  CD4-CD8-  T  cells  from patient  1 
were indeed monoclonal. In another case of idiopathic hy- 
pereosinophilic  syndrome,  a  monoclonal  expansion  of 
CD4+CD3 -  lymphocytes has  been  observed  (29).  Thus, 
monoclonal proliferation  of T  cell subsets  may frequently 
occur in this syndrome. 
In the  HIV-l-infected individual,  TCR. V~  expression 
was determined in CD4-CD8-  T  ceils and total lympho- 
cytes using specific mAb and flow cytometry. As shown in 
Fig. 4 B, the VJ3 repertoire of nonpurified T  cells  was het- 
erogeneously diverse.  In contrast,  none of the  mAbs used 
in this study stained purified CD4-CD8-  T  cells.  These re- 
suits suggest a limited number ofTCR  gene rearrangements 
compatible with the presence of an oligoclonal CD4-CD8- 
T  cell subset in patient 2. 
Functional Fas Molecules Are Not Expressed by CD4- CD8- 
T Cells.  Next,  we investigated  the  mechanism of CD4- 
CD8-  T  cell expansion.  The  Fas  antigen,  a  43-kD  mem- 
brane  protein and a member of the TNF  receptor family, 
was  originally  defined  by its  capacity  to  induce  apoptosis 
either by stimulation with agonistic mAb (30-32)  or by its 
natural ligand (33). Mutations of the Fas gene are associated 
with a massive accumulation of CD4-CD8-  T  cells  in as- 
sociation  with  autoimmune  disease  in  humans  (2,  3)  and 
mice  (34).  We therefore  considered  Fas  as a candidate re- 
sponsible for increased numbers ofCD4-CD8-  T  cells  ob- 
served in patients  1 and 2. 
Cell death of activated mature T  cells can be triggered by 
treatment with anti-Fas mAb (32).  Therefore,  we first ex- 
amined whether purified CD4-CD8-  T  cells express func- 
tional  Fas receptors.  While ~'-,25% of in vitro- or in vivo- 
activated nontransformed orJurkat T  cells died after anti-Fas 
mAb exposure,  anti-Fas mAb did not induce cell death in 
CD4-CD8-  T  cells  from patients  1  and  2  (Fig.  5).  The 
failure  of CD4-CD8-  T  cells to die was not because of a 
lack of activation, since the surface expression of the activa- 
tion markers  CD25  and HLA-DR were similar  compared 
to activated, control T  cells (Fig. 1 A, g and h, and data not 
shown).  Rather,  these  results  suggested  defective  Fas  ex- 
pression by CD4-CD8-  T  cells from both patients. 
Cell-surface  analysis  revealed  that  the  Fas  receptor was 
not expressed by CD4-CDS-  T  cells from patient 2  (Fig. 6 
A).  This  is  intriguing,  since  these  T  cells  expressed  the 
CD45RO +  memory  phenotype  (data  not  shown)  and 
should therefore demonstrate high surface staining by anti- 
Fas mAb (35).  CD8 + T  cells expressed high Fas levels and 
served as  a positive control in this  experiment  (Fig.  6 A). 
To confirm our data obtained from cell surface protein ex- 
pression,  we investigated  Fas  mRNA  expression by PCR.. 
The Fas mRNA  transcript was amplified using oligonucle- 
otide primers starting at nucleotide (nt)  170 (5' untranslated 
region)  and  ending at  nt  1336  (3'  untranslated  region)  of 
the published Fas cDNA sequence (19, 36).  The amplified 
product had the expected size of 1,167 bp in PBMC from 
patient 2  (mostly CD8 + T  cells)  which expressed Fas  (Fig. 
6  B).  In contrast,  the  CD4-CD8-  T  cells did not express 
detectable amounts of Fas mRNA  (Fig. 6 B), being consis- 
tent with the absence of Fas protein (Fig. 6 A). 
A  defect in Fas  expression  observed in lpr mutant  mice 
causes  lymphadenopathy  (34).  In  addition,  an  association 
between mutations within the Fas gene and lymphadenop- 
athy was recently observed in children (2, 3). This is prob- 
ably caused by the inability of Fas-deficient lymphocytes to 
undergo  apoptosis via the  Fas  pathway.  Similarly,  we  ob- 
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anti-CD3  (A), anti-CD4 (B), anti-CD5  (C), anti-CD8  (D), anti-TCRI3  (E), and anti-TCK~  (F).  Infiltrating T  cells were primarily CD3§  +, but 
CD4-CD5-CD8-TCR.~-. 
served an expansion of CD4-CD8-  T  cells that lacked Fas 
mRNA and protein expression in an adult HIV-l-infected 
individual. This patient, however, did not demonstrate hy- 
pergammaglobulinemia  or  any  sign  of autoimmunity,  a 
finding that stands in contrast to these murine and human 
disease models. In addition, the numbers ofCD4-CD8-  T 
cells in peripheral blood was less compared to that of chil- 
dren with the lymphoproliferative syndrome (1-3). More- 
over, PCR amplifications were performed using genomic 
DNA from PBMC of patient 2 and intron primers that am- 
phfy exons 3, 7, and 9 of the human Fas gene (3). Sequence 
analysis  of the  PCR.  products  revealed  no  abnormalities 
within the  Fas gene (data not shown).  These data exclude 
the possibility of any known germline mutation within the 
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Fas  gene  (3),  but suggest instead  that  Fas  abnormalities in 
this  HIV-infected individual  could  have  arisen  from  so- 
matic variations  in  gene  regulation,  since  CD4-CD8-  T 
cells  expressed no Fas while CD8 + T  cells  expressed nor- 
real levels of this protein. 
In contrast to the data observed in patient 2, the purified 
CD4-CD8-  T  cells of patient 1 showed high expression of 
the Fas protein (Fig. 7 A) and mRNA (Fig.  7 B). However, 
in  addition  to  the  expected  1,167-bp  PCR  product,  a 
smaller product of ~1,100  bp was seen in CD4-CD8-  T 
cells,  but not in  CD4 + T  cells  of that patient or in PHA- 
activated PBMC from a normal control individual  (Fig.  7 
B). The structure of the Fas PCK products of CD4-CD8- 
T  cells  from patient  1 was analyzed by DNA sequencing, Figure 3.  CD8 mKNA expression by CD4-CD8- T cells assessed  by 
PCR. Purified CD4-CD8- T cells from patients 1 and 2 did not express 
mR.NA for CD8(x or CD8~. PBMC from both patients, as well as puri- 
fied CD4 + T  cells from patient 1, served as controls. CD3~ expression 
confirmed that CD4-CD8- cells were T cells. 
and revealed that the larger PCIL product was indeed the 
anticipated Fas cDNA fragment. The smaller PCR product 
began with an identical nt sequence, but diverged at nt 700 
(Fig. 7  C-). Further sequence analysis showed that the smaller 
PCK product represented a Fas molecule with a 63-bp de- 
letion resulting in a  predicted protein that lacks 21  amino 
acid residues corresponding mostly to  the  transmembrane 
domain of Fas. 
The existence of such a molecule was recently described 
and characterized as a soluble, secreted form of Fas resulting 
from  alternative splicing (19,  37).  Supematants  from  cells 
transfected  with  this  alternative  splice  form  of Fas  could 
block  anti-Fas-induced apoptosis  (19,  37).  We  therefore 
analyzed whether the supernatant  of purified CD4-CD8- 
T  cells from patient 1 contained soluble Fas activity. Jurkat 
cells were cultured with antibody to Fas in the presence of 
supernatants derived from PBMC and different T  cell subsets 
of both  patients.  As  shown  in  Fig.  7  D,  supernatant  of 
CD4-CD8-,  but not ofCD4 + T  cells from patient 1 or of 
CD4-CD8-  T  cells from patient 2,  decreased by twofold 
the anti-Fas mAb-mediated death of the Jurkat T  cells. In 
addition,  other  T  cell  supernatants,  including  those  of 
PHA-activated  PBMC  from  normal  individuals,  did  not 
block anti-Fas-induced  Jurkat cell death. These results sug- 
gest that  CD4-CD8-  T  cells from  patient  1  indeed pro- 
duced soluble Fas protein,  which  neutralized the  anti-Fas 
antibody. It has been reported that PHA-activated PBMC 
Figure  4.  Monoclonal expansion of CD4-CD8- T cells in vivo. (A) 
Southern blot analysis  of  genes coding for the 13 chain of the TCR. DNA 
of colon tissue from patient 1 was digested with EcoRI (a), EcoRV (b), 
HindlI1 (c), and XbaI (d) restriction endonucleases.  A probe for the con- 
stant region of the 13 chain of the TCR. gene was used. The arrows indi- 
cate the positions of the rearranged alleles. The results indicate clear evi- 
dence for monoclonal T cell expansion. (t3) Analysis of TCR. V13 gene 
expression by CD4-CD8- T ceils assessed  by mAbs and flow cytornetry. 
None of the mAbs that were used stained purified CD4-CD8- T  cells 
from patient 2. In contrast, total lymphocytes demonstrate a normal distri- 
bution ofVI3 gene usage. 
from normal individuals may also  express mRNA  for  the 
apoptosis-inhibiting form of Fas (37), but the amounts syn- 
thesized by these cells were not enough to have significant 
effects in the Jurkat system. Taken together, our data make 
it likely that soluble Fas prevented the CD4-CD8-  T  cells 
of  patient 1 from undergoing Fas hgand-induced apoptosis. 
The programmed cell death of TCR-activated mature T 
cells  probably  serves  to  terminate  an  immune  response. 
Recent work provides evidence that autocrine stimulation 
of Fas is essential for TC1L-induced death of transformed T 
cells and activated PBMC  in vitro  (38--41).  Our data sug- 
gest  that  activated T  cells  expressing abnormal  Fas  avoid 
1076  Expansion of CD4-CD8- T Cells and Hypereosinophilia 40- 
o..7.. 
Jr 
@ 
"0 
m 
o 
T  ,....-.y, 
0  e,..-...-,  ,  ,y...,.-, 
,.:...,... 
,.:...... 
+:-:.;-', 
i:!:i:!:i:i  .....y... 
,::'::.'.', 
...-......, 
2o -  !:i::i::i::i:i 
,.::...., 
.........., 
,y.-...., 
,y...-.., 
,........-, 
........... 
10  -  iiiiiiiiii! 
....,-...,. 
_  -_  i  >:'N" 
::::::::I  ~::55~ 
:::::::::i !i!ii!iii 
￿9  .-.....-. 
:-:-:.:.:a  ".'.'.'. 
i  iiii;iiii: 
,..........  :  .......-. 
0  ->>>>3  ,---.-. 
!  I  !  I  I 
"  0  0  .o 
Figure 5.  Inhibition of Fas-induced cell death in CD4-CD8- T cells 
in vitro.  Anti-Fas mAb induced  significant cell death in vivo- and in 
vitro--activated T cells, as well as in Jurkat T celJs after an 18-h cell cul- 
ture. In contrast, anti-Fas mAb failed to induce cell death in highly acti- 
vated ex vivo CD4-CDS- T cells derived from patient 1 (a) or patient 2 
(b). Cell viability before and after 18-h  culture without anti-Fas mAb 
ranged between 95 and 98%. Data on PBMC and Jurkat represent mean 
values and standard deviations of three independent experiments. Data on 
in vivcr-activated  and -purified CD4-CD8- T cells are from one experi- 
ment that was performed in duplicate, which revealed identical results. 
cell death in vivo, and therefore strongly support the  hy- 
pothesis for a critical role of Fas-Fas ligand molecular inter- 
actions to  preserve peripheral T  cell homeostasis  (38-41). 
Thus, the unusual CD4-CD8-  T  cells accumulating in the 
two patients may represent previously activated peripheral 
T  cells that failed to undergo apoptosis at the end of an im- 
mune  response. Moreover, our data show that in two dif- 
ferent human diseases, Fas expression is critical for the nor- 
real function of the immune system. 
Production of Eosinophil  Survival Factors by CD4-CD8-  T 
Cells.  Since both patients of this study demonstrated in- 
creased numbers  of CD4-CD8-  T  cells  and  eosinophils, 
we  investigated whether  these  T  cells may  contribute  to 
the  eosinophilia  observed  in  vivo.  As  shown  in  Fig.  8, 
PHA~activated, but not resting PBMC  from control indi- 
viduals, secrete eosinophil survival factors. In contrast,  the 
resting PBMC  from both patients produced soluble prod- 
ucts that prolonged eosinophil survival in vitro. Addition of 
PHA to these cells did not significantly enhance the secre- 
tion  of eosinophil survival factors.  To  determine whether 
the double negative T  cell subset may produce eosinophil 
survival factors as observed previously in CD4 +  and CD8 + 
T  cell subsets derived from patients with bronchial asthma 
(6),  CD4-CD8-  T  cells were  purified by negative selec- 
tion (Fig. 1, Ad and Bd). Purified CD4-CD8-  T  cells from 
both  patients  constitutively secreted factors  that  extended 
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Figure 6.  Fas gene expression by CD4-CD8- T cells  from patient 2. 
(A) Two-color immunofluorescence analysis  to determine Fas protein ex- 
pression in lymphocytes. CD8 +, but not CD4-CD8- T cells, expressed 
Fas surface protein.  (/3) mRNA expression assessed by PCR.  Purified 
CD4-CD8- T cells did not express detectable Fas mRNA. In contrast, 
PBMC of this padent (primarily CD8 + T cells, see Fig. I A, b and c) ex- 
pressed Fas mRNA. Units are in basepairs.  As a control, amplification of 
the b-actin geue was performed from each template. 
the survival of eosinophi]s in vitro (Fig. 8). CD4-CD8-  T 
cells derived from patient  1  generated even more  eosino- 
phil  survival factors  than  purified  CD4 +  T  cells cultured 
under the same conditions. In addition, the supernatant of 
PBMC  (primarily CD8 + T  cells, Fig. 1 A, b and c) from pa- 
tient 2  also contained eosinophil survival factors, support- 
ing previously published work that CD8 +  T  cells have an 
active role in the regulation of the immune response (42). 
To  determine  which  cytokines prolong the  survival of 
eosinophils in culture, we tested multiple recombinant cy- 
tokines.  IL-3,  IL-5,  GM-CSF,  and  IFN-~/  are  cytokines 
that  inhibited  eosinophil  death  in  vitro.  Other  cytokines 
such as IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, TNF-ot, 
TNF-13,  and TGF-13 had no  effect on  eosinophil viability 
(data not shown). 
Since IL-3, IL-5, GM-CSF, and IFN-'y are able to pro- 
long eosinophil viability  in vitro, we measured the concentra- 
tion of  these cytokines in supematants of  purified CD4-CD8- 
T  cells by ELISA and  compared  them  with  other T  cell Figure 7.  Fas gene expression by CD4-CD8- T  cells from patient 1. (A) Two-color immunofluorescence analysis to determine Fas protein expression 
in purified CD4-CD8-  and CD4 + T  cells.  All CD4-CD8-, but not all CD4  + T  cells express Fas surface protein.  (B) mRNA expression assessed by 
PCR.  Purified CD4-CD8-  T  cells express high levels of Fas mRNA.  In addition,  a  distinct smaller PCP- product  of ~1,100 bp was observed in 
CD4-CD8-  T  cells, which was not expressed in PHA-activated PBMC from normal donors nor in the CD4 + T  cell subset. As a control, amplification 
of the [3-actin gene was performed from each template. (C) Sequence analysis ofFas PCR products. The smaller PCR product observed in CD4-CD8- 
T  cells represents a soluble form of Fas that lacks the hydrophobic transmembrane domain. This PCR product started with an identical nt sequence, but 
began to differ at nt 700 (arrow).  (19) Soluble Fas activity in supematants from purified T  cells and PBMC of  patient 1 (a) and patient 2 (b) compared to su- 
pernatants from resting and PHA-activated PBMC of three normal individuals. Jurkat cells were  cultured in the presence of supernatant and anti-Fas 
mAb. Supernatant from CD4-CD8- T  cells of patient 1 inhibited '~50% of the Jurkat cell death induced by anti-Fas mAb. in contrast, supernatant from 
CD4  + T  cells of the same patient did not contain detectable soluble Fas activity. In addition, supematants from CD4-CD8- T  cells and PBMC of patient 
2 or resting and PHA-activated PBMC of normal individuals did not contain detectable soluble Fas activity. Data on normal PBMC and control experi- 
ments (without supernatants) represent mean values and standard deviations of three independent experiments. Data on PBMC and purified T  cells from 
both patients are from one out of two experiments that showed identical results. 
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Figure 8.  Effects  ofnonstimulated or stimulated T cell supernatants on 
eosinophil survival. PHA-activated, but not resting PBMC from control 
individuals, produce eosinophil survival factors (n =  6). In contrast, su- 
pernatants from resting PBMC and purified CD4-CD8- T cells derived 
from both hypereosinophilic patients prolong eosinophil viability. Data 
on controls (no treatment, GM-CSF, supernatants from resting and PHA- 
activated PBMC) represent mean values and standard deviations of  six in- 
dependent experiments. Data on supernatants from PBMC and purified T 
cells of  both patients are from one experiment that was performed in du- 
plicate, which revealed identical results. 
populations from the same patient,  as well as from control 
individuals.  As shown in Table  1, activated, but not resting 
PBMC from normal control individuals  secrete significant 
amounts of IL-3, IL-5, GM-CSF,  and IFN-%  In contrast, 
the  resting  PBMC  from both  patients  released  significant 
amounts  of IL-3  and  IL-5,  but  not  IFN-~/  or  GM-CSF 
(Table  1).  This suggests that these PBMC were previously 
activated in vivo. Patient 2  released much higher amounts 
of IL-5 compared to patient  1,  consistent with the higher 
degree of peripheral  blood eosinophilia  at the  time  of the 
study.  In addition,  the  capacity of PHA-activated PBMC 
to  secrete  IL-5  seemed  to  be  much  higher  in  patient  1 
compared  to  normal  control  individuals.  The  purified 
CD4-CD8-  T  cells  from patient  1, in the absence of any 
stimulating agent,  released significant amounts of IL-3 and 
IL-5,  but  no  detectable  amounts  of IFN-~/  or  GM-CSF 
(Table 1). In contrast, purified CD4 + T  cells from the same 
patient  produced  high  concentrations  of IFN-%  but  not 
IL-3,  IL-5,  or  GM-CSF  (Table  1).  These  results  suggest 
that both CD4-CD8-  and CD4 + T  cell subsets of patient 
1 contributed  to the  eosinophilia  observed in vivo, how- 
ever, by producing different cytokines. Furthermore, PBMC 
(primarily CD8 + T  cells,  see Fig.  1 A, b and c) and the pu- 
rified  CD4-CD8-  T  cells  from  patient  2  spontaneously 
produced  high  amounts  of IL-5,  whereas  levels  of IL-3, 
GM-CSF, and IFN-~/were low or undetectable  (Table  1). 
Taken  together,  these  results  demonstrate  that  the 
CD4-CD8-  T  cells derived from the patient with hyper- 
eosinophilic syndrome and from the HIV-l-infected indi- 
vidual  secreted  a  cytokine profile  that  is  characteristic  for 
Th2 cells (43). Moreover, they are in agreement with recent 
findings  describing the  establishment  and  cytokine profile 
ofCD4-CD8-  T  cell clones derived from HIV-l-infected 
individuals  (44).  Our results  also  support  the  notion  that 
IL-5 plays a role in the pathogenesis of eosinophilia in hu- 
man disease (9,  45, 46) and in animal models (47). 
Cytokine  mRNA Expression by  CD4-CD8-  T  Cells and 
Eosinophils.  Since purified  T  cell subsets  in both patients 
secreted,  at  least  partially,  differing  cytokine  profiles,  we 
next  examined  the  expression  of these  cytokines  at  the 
RNA level using the reverse transcriptase  PCR technique. 
As shown in Fig. 9 A, CD4-CD8-  T  cells from patient  1 
Table  1.  Cytokine  Production by CD4-CD8- T Cells Compared to Other T Cell Subsets 
IL-3  IL-5  GM-CSF  IFN-~/ 
pg/ml 
Patient 1 
PBMC  11  15  8  < 100 
PBMC +  PHA  29  669  299  260 
CD4-CD8- T cells  34  26  <5  <100 
CD4+CD8  -  T cells  <5  <5  <5  318 
Patient 2 
PBMC (primarily  CD8 +)  25  145  <5  <5 
CD4-CD8- T cells  <5  156  <5  <5 
Control individuals  (n =  6) 
PBMC  <5  <5  10  <100 
PBMC +  PHA  47  77  283  459 
1079  S~non et ~. Figure 9.  Cytokine mRNA expression by CD4-CD8- T cells assessed 
by PCR. (A) Patient with idiopathic hypereosinophilic  syndrome (patient 
1). Purified CD4-CD8- T cells expressed high levels of mRNA for the 
Th2  cytokines IL-4, IL-5, and IL-6. However, they also expressed all 
other investigated cytokine genes. The CD4 + T cell subset demonstrated 
high level mRNA expression for the Th 1 cytokines IFN-~ and TNFm. 
(/3) HIV-l-infected  individual (patient 2). Purified CD4-CD8- T cells 
showed a prominent IL-5 mRNA expression. The CD8 § T cell subset 
produced mRNA for Th  1 and Th 2 cytokines. Only CD8  §  but not 
CD4-CD8- T cells, expressed IL-4 and may therefore account for high 
IgE levels. Neither CD4-CD8- nor CD8* T cells expressed mRNA for 
IFN-31. 
expressed more IL-3 and IL-5 mRNA  than CD4  §  T  cells 
from the same patient.  In contrast,  CD4  +  T  cells may ex- 
press  more  IFN-~/  mRNA.  Furthermore,  CD4-CD8-  T 
cells derived from patient  1 expressed IL-2 mRNA. Thus, 
at this level of  sensitivity, we demonstrated that CD4-CD8- 
T  cells can express, besides Th2 (IL-4, IL-5, and IL-6), also 
some Thl  (IL-2, IFN-'y, and TNF-ot) cytokines. These data 
are  in agreement with  the view that categorizing for only 
two types of T  cell responses may be an oversimplification 
(48, 49). 
The CD4-CD8-  T  cells  from patient 2  showed a more 
restricted spectrum of cytokine gene expression  (Fig. 9/3). 
The most prominent cytokine mRNA was IL-5. In addition, 
the  PBMC  population  of this  patient  (primarily  CD8 +  T 
cells)  also demonstrated high levels of IL-5 mRNA in addi- 
tion  to  IL-3  and  IL-4,  and  low  levels  of IL-2,  IL-6  and 
TNF-ot mRNA  (Fig.  9  B).  Thus,  both  CD4-CD8-  and 
CD8 §  T  cells  from patient  2  are  hkely  to  cause  eosino- 
philia.  In  contrast,  only  CD8 +,  and  not  CD4-CD8-,  T 
cells  are  a  source  of IL-4 mRNA  that  may stimulate  IgE 
production  in  this  HIV-infected  patient.  CD8  +  T  cells 
were  recently associated with  high  IgE production in  pa- 
tients  with  progression  toward  AIDS  (44,  50).  Interest- 
ingly,  the  highly activated  T  cells  of this  HIV-l-infected 
individual  did not express  mRNA  for IFN-~/.  These  data 
are  in  agreement  with  the  hypothesis  that  progression  to 
AIDS is  characterized by loss of IFN-~/and  IL-2 produc- 
tion concomitant with increases in IL-4 (12). 
Taken together, the results on mRNA  expression of cy- 
tokines with eosinophil antiapoptotic properties are consis- 
tent with the ELISA results (Table 1). Moreover, at the level 
of PCR  sensitivity,  we  demonstrated  that  CD4-CD8-  T 
cells from both patients  expressed  some mRNA  for GM- 
CSF, even though the protein was not detectable using the 
ELISA technique (Table 1). 
We also examined cytokine gene  expression by eosino- 
phils  derived  from patient  1.  It is  known that  eosinophils 
have the capacity to produce and release  certain cytokines 
(15). This suggests that the eosinophil is not only an effec- 
tor  cell  at  the  end  of an  immunological  cascade,  but  can 
also  actively participate  in  a  cytokine  network  regulating 
the  immune  response.  As shown  in  Fig.  9  A,  eosinophils 
from patient  1 expressed mKNA  for IL-3, IL-5, and IL-6, 
but not for IL-2, IL-4, TNF-c~,  IFN~,  or GM-CSF.  The 
expression  of IL-3,  IL-5,  and  IL-6  by  eosinophils  is  in 
agreement with previously pubhshed work (51-53). 
In summary, we have demonstrated that blood and tissue 
eosinophilia  can  be  associated  with  increased  numbers  of 
CD4-CD8-  T  cells.  The expansion ofCD4-CD8-  T  cells 
may occur in vivo as  a  result  of somatic variations  in  Fas 
expression and function occurring quite late in life. Failure 
to express  Fas  or expression of a soluble  form of Fas were 
associated  with  inhibition  of apoptosis  in  these  T  cells. 
Moreover,  activated T  cells that do not undergo apoptosis 
are  potentially  dangerous.  For  example,  CD4-CD8-  T 
cells expressed cytokines promoting eosinophil survival and 
may therefore  have  inhibited  eosinophil  apoptosis in vivo 
(8).  Thus,  our findings further point to the importance  of 
dysregulation of programmed cell death in pathogenic pro- 
cesses  (54). 
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